Modality
Degrader
MOA
CAR-T CD19
Target
PLK4
Pathway
Tau
Thymoma
Development Pipeline
Preclinical
~May 2013
→ ~Aug 2014
Phase 1
~Nov 2014
→ ~Feb 2016
Phase 2
~May 2016
→ ~Aug 2017
Phase 3
~Nov 2017
→ ~Feb 2019
NDA/BLA
May 2019
→ Oct 2029
NDA/BLACurrent
NCT03929248
328 pts·Thymoma
2019-05→2026-07·Recruiting
NCT05436494
832 pts·Thymoma
2021-11→2029-10·Completed
1,160 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-113mo awayPh3 Readout· Thymoma
2029-10-223.6y awayPh3 Readout· Thymoma
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
NDA/BLA
Recruit…
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2026-07-11 · 3mo away
Thymoma
Ph3 Readout
2029-10-22 · 3.6y away
Thymoma
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03929248 | NDA/BLA | Thymoma | Recruiting | 328 | EASI-75 |
| NCT05436494 | NDA/BLA | Thymoma | Completed | 832 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Talasotorasib | Exelixis | Preclinical | APOC3 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ILM-2412 | Illumina | Phase 3 | PLK4 |